California Institute of Technology

City of Hope

University of California

The United States Government As Represented by the Department of Veterans Affairs

Other

Seiko Epson Corporation

The General Hospital Corporation

Korea Advanced Institute of Science and Technology

University of Nevada

Clty of Hope

William A Goddard, Iii

John J Rossi

Lisa Scherer

Si-ping Han

Robert D Barish

Andres Jaramillo-Botero

Si-Ping Han

Ravinder Abrol

Stephen Pandol

Mark Menna

James R Heath

Margaret A Ryan

Mario R Blanco

Shiao-Pin S Yen

Jamil Tahir-Kheli

Margie L Homer

Adam Kisor

April D Jewell

Abhijit V Shevade

Charles Taylor

Gyeong S Hwang

Yuri Bunimovich

Kenneth S Manatt

Akram Boukai

Hareem T Maune

Marwa Ben Haj Salah

Yuzuru Sato

Mamadou Samba Diallo

Masamitsu Uehara

Masayasu Miyata

Yongchun Tang

Guido Marcucci

Yuki Matsuda

Ya-Huei Kuo

Paul W K Rothemund

Sheng Wu

Erik Winfree

Nagarajan Vaidehi

Wely Floriano

Roy A Periana

Marc William Bockrath

Spencer E Hall

Adam R Griffith

Victor Wai Tak Kam

Seong-Jik Park

Jamil Tamir-Kheli

Andrei Deev

Manki Cho

Steve L Palm

Dean M Philipp

Richard P Muller

Mu-Jeng Cheng

Christopher Brandow

Ross Fu

Saumya Das

Ane Miren Salvador Garicano

Julia Derogatis

Weiqiao Deng

Sahil Sagar

Alessandro Fortunelli

Qi An

Rene J Trabanino

Robin Hu

Disclosed herein are conditional siRNAs activatable by pro-hypertrophic RNA sequences and use thereof for treating conditions such as cardiac hypertrophy. The conditional siRNAs target calcineurin or HDAC2.

Conditional-siRNAS and uses thereof in treating cardiac hypertrophy

Provided herein are screening methods to select catalysts having a desired set of target properties from a reference catalyst, and catalysts so obtained, as well as related catalysts material, composition, methods and systems.

Screening methods and related catalysts, materials, compositions, methods and systems

Disclosed herein are multi-way oligonucleotide junctions for delivering one or more cargo molecules to a biological target and method of making such junctions. The oligonucleotide junctions are formed by two or more oligonucleotides and are stable outside the cell and easily dissociate inside the cell to release the cargo molecule(s). One or more cargo molecules as well as delivery ligand can be loaded to the junctions for targeted delivery. Also disclosed are nanostructures including one or more junctions attached to each other for delivering two or more cargo molecules.

Meta-stable oligonucleotides junctions for delivery of therapeutics

Disclosed herein are programmable, conditionally activated small interfering RNA constructs (Cond-siRNAs) and methods of making and using the same as therapeutic agents. The Cond-siRNA comprises a sensor strand, a core strand, and a guide strand, which crossover to form a sensor duplex and a RNAi duplex attached to each other to form a single structure. Upon binding an input strand to the sensor strand, the Cond-siRNA is activated and releases RNAi targeting a desired gene.

Programmable conditional SIRNAS and uses thereof

Disclosed herein are conditional siRNAs activatable by CBF&#x3b2;-MYH11 oncogenic gene and use thereof for treating conditions such as acute myeloid leukemia (AML). The conditional siRNAs target MCL-1 or HDAC8.

Conditional-siRNAS and uses thereof in treating acute myeloid leukemia

Filtration membrane comprising polymeric nanofibers and/or microfibers attaching dendrimer component presenting reactive sites selective for chemicals to be filtered, and related nanofibers and microfibers, composite materials, compositions, methods and system.

Filtration membranes, and related nano and/or micro fibers, composites, methods and systems

Provided herein are bitter taste receptor ligands, related agents, combinations, compositions, methods and systems for modulating release of a metabolic hormone in vitro and in vivo from cells of the GI tract of an individual.

Methods and systems for modulating hormones and related methods, agents and compositions

Methods and devices for controlling thermal conductivity and thermoelectric power of semiconductor nanowires are described. The thermal conductivity and the thermoelectric power are controlled substantially independently of the electrical conductivity of the nanowires by controlling dimensions and doping, respectively, of the nanowires. A thermoelectric device comprising p-doped and n-doped semiconductor nanowire thermocouples is also shown, together with a method to fabricate alternately p-doped and n-doped arrays of silicon nanowires.

Methods and devices for controlling thermal conductivity and thermoelectric power of semiconductor nanowires

A method for practical prediction of the three-dimensional structure of &#x3b1;-helical membrane proteins (HMPs) is described. The method allows one to predict the binding site and structure for strongly bound ligands. The method combines a protocol of computational methods enabling a complete ensemble of packings to be sampled and systematically reducing this ensemble to progressively more accurate structures until at the end there remain a few that might be functionally relevant and likely to play a role in all binding and activation processes. This method is well suited to automatic operation making it practical to obtain, for example, the ensemble of important structures for all human GPCRs. With this ensemble of all active GPCR structures in the human body, an infimum method is presented to maximize efficacy toward the selected target while minimizing binding to all other GPCRs to eliminate toxicity arising from cross-reacting with other GPCRs (a most common source of drug failure). This infimum method is broadly applicable to any set of proteins where a ligand is desired to be able to modulate the function of one protein while not affecting the function of other proteins.

Methods for predicting three-dimensional structures for alpha helical membrane proteins and their use in design of selective ligands

Provided herein are signal activatable molecular constructs for delivery of molecules and related components, compositions, methods, and systems, having a 17 to 30 bp targeting domain duplex RNA, at least one protection strand having a protection segment and linker segment and a sensor strand having a displacement segment and a toehold segment, in which in an inactive conformation the protection segment and the displacement segment form a sensor domain duplex polynucleotide covalently attached to the targeting domain and presenting the toehold segment for binding to a signal molecule. In an active conformation the sensor strand is bound to the signal molecule and is detached from the at least one protection strand and from the targeting domain; and the targeting domain attaches the at least one protection strand in a configuration allowing processing by Dicer and/or an Argonaute enzyme.

Signal activatable constructs and related components compositions methods and systems

The invention provides compositions and methods for signal activated RNA interference (saRNAi), preferably in vivo. The invention provides polynucleotides that switches between an inactive form and an active form upon covalent or non-covalent interaction with one or more specific chemical signals, such as disease-specific mRNA, miRNA, or other cellular RNA products with sequences that characterize diseased states of the cell. The interaction between the subject polynucleotides and the signals is preferably mediated by hybridization, which exposes, facilitates the formation, and/or allows the formation of a substrate that can be processed by proteins of the RNAi pathway (such as Dicer). The input and output of multiple different polynucleotides of the invention can form an in vivo signaling network. In addition, the multiple input signals can be integrated to modulate the activity of the subject polynucleotides.

Signal activated RNA interference

A detector apparatus includes a field-effect transistor configured to undergo a change in amplitude of a source-to-drain current when at least a portion of a charge-tagged molecule translocates through the nanopore. In some implementations, the field-effect transistor is a carbon nanotube field effect transistor and the nanopore is located in a membrane. In other implementations, the field-effect transistor is a carbon nanotube field effect transistor and the nanopore is implemented in the form of a nano-channel in a semiconductor layer.

Using a field effect device for identifying translocating charge-tagged molecules in a nanopore sequencing device

A linker polynucleotide for attaching a nanomaterial to a polynucleotidic platform and related nanoassemblies, arrangements, structures, methods and systems.

Polynucleotides and related nanoassemblies, structures, arrangements, methods and systems

Described herein are catalysts for activation of an R&#x2014;H bond in a R&#x2014;H substrate and related catalytic matrices, compositions, methods and systems.

Methods for providing bond activation catalysts and related catalysts, systems, and methods

Provided herein are bitter taste receptor ligands, related agents, combinations, compositions, methods and systems for modulating release of a metabolic hormone in vitro or in vivo from cells of the GI tract of an individual.

Growing community of inventors

Pasadena, CA, United States of America

William A Goddard, Iii